Global patterns of hemophilia drug trials, hemophilia care, and health care measures
Most HDT sites were located in high-income countries, although a substantial proportion were in upper middle-income countries. A small but increasing number of trials were conducted in lower-middle-income countries, where factor usage is relatively low. This study provides evidence on the global distribution of HDT and raises questions regarding the generalizability, barriers, opportunities, and ethics of trials for a rare bleeding disorder.
Authors
- Tyler W. Buckner (ORCID: https://orcid.org/0000-0003-1954-4385)
- Theresa Gillespie (ORCID: https://orcid.org/0000-0001-8734-716X)
- Christine L. Kempton (ORCID: https://orcid.org/0000-0002-2391-2016)
- Leonard A. Valentino (ORCID: https://orcid.org/0000-0002-7927-6418)
- Ana G. Antun
- Duc Quang Tran (ORCID: https://orcid.org/0000-0002-6347-4452)
- Stacey A. Fedewa (ORCID: https://orcid.org/0000-0002-3624-6382)
- Lorraine Cafuir
- Andee Koo
Institutions
- Rush University Medical Center (US)
- Emory University (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.rpth.2025.102714
- Citations
- 4
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 7.08